- Home
- KLRS vs SRTS Comparison
KLRS vs SRTS Comparison
Compare KLRS & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- SRTS
- Stock Information
- Founded
- KLRS 2019
- SRTS 2010
- Country
- KLRS United States
- SRTS United States
- Employees
- KLRS N/A
- SRTS N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- SRTS Medical/Dental Instruments
- Sector
- KLRS Health Care
- SRTS Health Care
- Exchange
- KLRS Nasdaq
- SRTS Nasdaq
- Market Cap
- KLRS 46.0M
- SRTS 52.9M
- IPO Year
- KLRS N/A
- SRTS 2016
- Fundamental
- Price
- KLRS $4.97
- SRTS $3.32
- Analyst Decision
- KLRS Strong Buy
- SRTS Strong Buy
- Analyst Count
- KLRS 2
- SRTS 3
- Target Price
- KLRS $23.00
- SRTS $8.00
- AVG Volume (30 Days)
- KLRS 175.7K
- SRTS 78.4K
- Earning Date
- KLRS 11-15-2025
- SRTS 11-06-2025
- Dividend Yield
- KLRS N/A
- SRTS N/A
- EPS Growth
- KLRS N/A
- SRTS N/A
- EPS
- KLRS N/A
- SRTS N/A
- Revenue
- KLRS N/A
- SRTS $37,564,000.00
- Revenue This Year
- KLRS N/A
- SRTS N/A
- Revenue Next Year
- KLRS N/A
- SRTS $47.33
- P/E Ratio
- KLRS N/A
- SRTS N/A
- Revenue Growth
- KLRS N/A
- SRTS 3.29
- 52 Week Low
- KLRS $2.14
- SRTS $3.03
- 52 Week High
- KLRS $24.15
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- KLRS 49.92
- SRTS 51.30
- Support Level
- KLRS $4.70
- SRTS $3.13
- Resistance Level
- KLRS $5.30
- SRTS $3.45
- Average True Range (ATR)
- KLRS 0.41
- SRTS 0.17
- MACD
- KLRS -0.06
- SRTS 0.01
- Stochastic Oscillator
- KLRS 67.48
- SRTS 51.35
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.